Sign In
Buy SANA
$3.13
-0.120 (-3.69%)
At Close: Jul 31, 2026
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages
01:45am, Thursday, 30'th Jul 2026
Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat Ratings report
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
10:09am, Wednesday, 29'th Jul 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
11:51am, Monday, 20'th Jul 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Sana (SANA) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 15'th Jul 2026
Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
09:00am, Wednesday, 01'st Jul 2026
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presen
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:22am, Wednesday, 10'th Jun 2026
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
06:11pm, Tuesday, 02'nd Jun 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
Sana Biotechnology to Present at June 2026 Investor Conferences
04:05pm, Wednesday, 27'th May 2026
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
09:00am, Friday, 15'th May 2026
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold a
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:30am, Wednesday, 13'th May 2026
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Monday, 11'th May 2026
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
04:05pm, Tuesday, 05'th May 2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract
